Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Proceedings of the 8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)

Oral presentation

Etiology and molecular pathogenesis of RA; how can we best use European initiatives to advance our knowledge?

Lars Klareskog

  • Correspondence: Lars Klareskog

Author Affiliations

Rheumatology Unit, Department of Medicine, Karolinska Institutet/Karolinska University Hospital, 171 76 Stockholm, Sweden

Arthritis Research & Therapy 2012, 14(Suppl 1):O3  doi:10.1186/ar3558


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/14/S1/O3


Published:9 February 2012

© 2012 Klareskog; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral presentation

Understanding etiology and molecular pathogenesis of rheumatoid arthritis is key to the development of precise prevention and curative therapy for this disease. Recent progress on how genes and environment interact in causing immune reactions that may induce arthritis in humans as well as in mice, have provided a conceptual basis for the development of new prevention and treatment strategies which need to be different for different subsets of RA. In order to bring this emerging knowledge to the level where basic and clinical academic science can collaborate with industry for rapid development of the potential new therapies, there is a need for closer collaboration between basic and clinical scientists from many centers, and for increased collaboration between industry and academia in translational medicine.

In Europe, both the EU-funded framework programs and the EU and industry funded Innovative Medicine Initiative (IMI) funder programs in rheumatology are geared to accomplishing these goals. This presentation will be concerned both with the scientific basis of these programs and with a descriptions of the challenges and potential promises that these new collaborative programs offer to rheumatology.